Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in High Risk Smoldering Multiple Myeloma
NCT02943473Phase 2Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- May 2017
- Primary completion
- Sep 2019
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in smoldering multiple myeloma (SMM), sponsored by Icahn School of Medicine at Mount Sinai. Started May 2017; status: terminated.
02
Drugs
ibrutinib
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT02943473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943473.